Quick Order

DLL4 / Delta-4 Antibody, Rabbit MAb

DatasheetReviewsRelated ProductsProtocols
Mouse DLL4 Antibody Product Information
Immunogen:Recombinant Mouse DLL4 protein (Catalog#50640-M08H)
Clone ID:006
Ig Type:Rabbit IgG
Concentration:
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Mouse DLL4 (rM DLL4; Catalog#50640-M08H; NP_062327.2; Met 1-Pro 525).
Mouse DLL4 Antibody Usage Guide
Specificity:Mouse DLL4 / Delta-4
No cross-reactivity in with
Human DLL4 / Delta-4
Application:ELISA

ELISA: 0.1-0.2 μg/mL

This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse DLL4. The detection limit for Mouse DLL4 is approximately 0.00245 ng/well.

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Other DLL4 Antibody Products
Reactivity: Human  
Application: ELISA  
    10171-MM15-100
    10171-MM15-50
    10171-MM15-200
    100 µg 
    50 µg 
    200 µg 
    Add to Cart
    Reactivity: Human  
    Application: ELISA  
      10171-RP01-100
      10171-RP01-200
      10171-RP01-400
      100 µg 
      200 µg 
       
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10171-RP02-50
        10171-RP02-100
        10171-RP02-200
        50 µg 
        100 µg 
        200 µg 
        Add to Cart
        Reactivity: Human  
        Application: ELISA  
          10171-MM06-50
          10171-MM06-100
          10171-MM06-200
          50 µg 
          100 µg 
          200 µg 
          Add to Cart
          Reactivity: Human  
          Application: ELISA  
            10171-R003-50
            10171-R003-100
            50 µg 
            100 µg 
            Add to Cart
            Reactivity: Mouse  
            Application: ELISA  
              50640-RP01-100
              50640-RP01-200
              50640-RP01-400
              100 µg 
              200 µg 
               
              Add to Cart
              Reactivity: Mouse  
              Application: ELISA  
                50640-RP02-50
                50640-RP02-100
                50640-RP02-200
                50 µg 
                100 µg 
                200 µg 
                Add to Cart
                DLL4/Delta-like 4 Background

                Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

                Mouse DLL4/Delta-like 4 References
              • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
              • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
              • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
              • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
              • Product nameProduct name
                Size / Price
                Catalog: 50640-R006-50
                List Price: 
                Price:      (You Save: )
                Size:
                50 µg
                100 µg
                Quantity:+-
                AvailabilityIn Stock
                Bulk Discount InquiryAdd to Cart
                All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
                Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"